Guang Biao Zhou | Cancer immunology | Best Researcher Award

Published on by Global Academic Awards

Prof. Guang Biao Zhou | Cancer immunology | Best Researcher Award

Prof. Guang Biao Zhou, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

Prof. Guang-Biao Zhou is a renowned cancer biologist and Deputy Director of the State Key Laboratory of Molecular Oncology at the National Cancer Center, Chinese Academy of Medical Sciences. His research focuses on 🫁 environmental lung carcinogenesis and cancer therapeutics, exploring the roles of genomic changes and non-coding RNAs in pollution-induced lung cancer. He has identified key factors like AhR, CXCL13, and CDC34 in tobacco and air pollution-related cancer pathways. 📚 With over 150 peer-reviewed publications, Dr. Zhou also serves as Executive Deputy Editor-in-Chief of Frontiers of Medicine and CAE Transactions on Medicine.

Publication Profile

Scopus

Orcid

🎓 Education & Qualifications

Prof. Guang-Biao Zhou earned his MD and Ph.D. in Medicine from the prestigious School of Medicine at Shanghai Jiao Tong University, Shanghai, China 🏛️. His academic training spanned from August 25, 2000, to July 1, 2003, equipping him with a solid foundation in medical science and research 🧬. This rigorous education laid the groundwork for his future contributions to oncology, particularly in environmental lung carcinogenesis and therapeutic innovation 🫁. Prof. Zhou’s qualifications reflect both academic excellence and a strong commitment to advancing medical knowledge 📚, shaping his path as a leading figure in cancer biology

💼 Professional Experience

Prof. Guang-Biao Zhou has held esteemed positions across leading Chinese research institutions. Since October 2018, he has been serving as a Professor at the State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences in Beijing 🏥. Prior to this, from 2009 to 2018, he was a Professor at the State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences 🧫. His earlier tenure from 2005 to 2009 was at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 🧬, marking a strong trajectory in biomedical research leadership

Research Focus

Prof. Dr. Guang-Biao Zhou is a leading researcher in the fields of lung cancer biology 🫁, molecular oncology 🧬, and immunotherapy 💉. His work focuses on the molecular mechanisms of tumor progression, such as metabolic reprogramming, apoptosis, and immune regulation. He has contributed to high-impact studies involving non-small cell lung cancer, cancer vaccine development, PD-L2-mediated immune responses, and thalassemia treatments. His interdisciplinary approach bridges genomic regulation, mitochondrial-associated cell death, and drug resistance pathways, aiming to improve prognostic markers and therapeutic targets. Zhou’s research is frequently published in top-tier journals like Molecular Cell, Nature Biomedical Engineering, and Cell Discovery.

Conclusion

Prof. Guang-Biao Zhou is highly suitable for the Research for Best Researcher Award. His work not only advances scientific understanding but also offers practical implications for improving global health outcomes. 

Publication Top Notes

  • 🧬 Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer – Cancer Letters, 2024 | 📅 2024 | DOI: 10.1016/j.canlet.2024.216929

  • ⚡ CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in NSCLC – Cell Discovery, 2024 | 📅 2024 | DOI: 10.1038/s41421-023-00633-0

  • 🧪 10,11-Dehydrocurvularin attenuates inflammation via NLRP3 suppression – Chinese Journal of Natural Medicines, 2023 | 📅 2023 | DOI: 10.1016/S1875-5364(23)60418-2

  • 🌫️🧬 Air pollution, EGFR mutation, and cancer initiation – Cell Reports Medicine, 2023 | 📅 2023 | DOI: 10.1016/j.xcrm.2023.101046

  • 🌿✨ Corrigendum: Promising anticancer activities of Centipeda minima compounds – Phytomedicine, 2023 | 📅 2023 | DOI: 10.1016/j.phymed.2022.154472

  • 🧠🧬 Alternative splicing of FAK in pancreatic and breast neuroendocrine tumors – Frontiers of Medicine, 2023 | 📅 2023 | DOI: 10.1007/s11684-023-1009-7

  • 🛡️🧫 CD47 in tumor immune evasion and targeted therapy – Journal of Sichuan Univ. (Med Sci), 2023 | 📅 2023 | DOI: 10.12182/20230560101

  • 🧪🧬 Nuclear AhR and membranous PD-L1 predict PD-1 response in NSCLC – Signal Transduction & Targeted Therapy, 2023 | 📅 2023 | DOI: 10.1038/s41392-023-01416-5

  • 🚬🛡️ Tobacco carcinogen induces IDO1 and immune suppression – Signal Transduction & Targeted Therapy, 2022 | 📅 2022 | DOI: 10.1038/s41392-022-01127-3

  • 📢🧬 Correction: AhR mediates tobacco-induced PD-L1 and immunotherapy response – Nature Communications, 2022 | 📅 2022 | DOI: 10.1038/s41467-022-30871-x

Xiang Yu | Regional Immunity | Best Researcher Award

Published on by Global Academic Awards

Prof. Xiang Yu | Regional Immunity | Best Researcher Award

Prof. Xiang Yu, Hainan University, China

Prof. Xiang Yu is a distinguished immunologist and professor at Hainan University’s School of Biomedical Engineering. He specializes in regional immunity, with a focus on liver immunity and immune visualization. Holding a PhD from Huazhong University of Science and Technology, he has significantly contributed to tumor immunology and nanomedicine. Prof. Yu has published over 59 SCI-indexed papers, including highly cited works in Nature Communications and ACS Nano. His research innovations, including nanovaccines and biomimetic probes, have garnered international recognition. He has supervised numerous doctoral students and received multiple awards, including the Young Scholar Award from the Chinese Society of Immunology.

Publication Profile

Scopus

Orcid

Education 🎓📖

Prof. Xiang Yu obtained a Bachelor’s degree in Clinical Medicine from Wuhan University of Science and Technology in 2013. He later pursued a PhD in Biomedical Engineering at Huazhong University of Science and Technology, graduating in 2019. His doctoral research focused on immune microenvironment regulation, leading to groundbreaking findings in immune visualization and nanomedicine. During his academic journey, he developed expertise in tumor immunology, bio-nanotechnology, and immunotherapeutics. His education laid the foundation for his pioneering work in targeted liver immunity and innovative vaccine designs.

Experience 🏫🔬

Since 2019, Prof. Xiang Yu has been a professor of immunology at Hainan University, mentoring graduate students and leading cutting-edge research projects. His expertise in immune-targeted therapies has driven advancements in biomedical imaging and tumor vaccines. Over the years, he has published over 59 high-impact journal articles, collaborated on international research projects, and contributed to multiple patents. He also holds editorial roles in prestigious journals, serves as a reviewer for SCI-indexed publications, and has been an invited speaker at global immunology conferences.

Awards and Honors 🏆🎖

Prof. Yu has received four major awards, including the Young Scholar Award from the Chinese Society of Immunology. His groundbreaking research has been recognized with the Annual Best Paper Award by Journal of Nanobiotechnology. He has also earned two ESI Highly Cited Paper awards, highlighting his significant impact in immunology and nanomedicine. His students have won national and municipal prizes in academic competitions under his mentorship.

Research Focus 🔬🧬

Prof. Xiang Yu’s research revolves around regional immunity, particularly liver immunity and immune visualization. His work includes bee venom-based liver endothelial targeting, whole-tumor-cell nanovaccines, and biomimetic probes for inflammatory diseases. His studies have led to novel immune regulation strategies for cancer metastasis and autoimmune disorders. His interdisciplinary approach combines bioengineering, nanotechnology, and immunology to develop innovative diagnostic and therapeutic solutions.

Publication Top Notes

  • Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis (Nature Communications, 2019)

  • Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response (Nature Communications, 2020)

  • Metastatic status of sentinel lymph nodes in breast cancer determined with photoacoustic microscopy via dual-targeting nanoparticles (Light: Science & Applications, 2020)

  • Biomimetic nanoplatform with selectively positioned indocyanine green for accurate sentinel lymph node imaging (Nanoscale, 2023)

  • Aptamer-modified melittin micelles efficiently inhibit osteosarcoma deterioration by inducing immunogenic cell death (Colloids and Surfaces B: Biointerfaces, 2025)

  • Breaking CHIPS-Mediated immune evasion with tripterin to promote neutrophil chemotaxis against MRSA infection (International Immunopharmacology, 2024)

  • Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Monobenzone-Induced Vitiligo in Mice (International Journal of Molecular Sciences, 2024)

  • Mitochondrial stress response in drug-induced liver injury (Molecular Biology Reports, 2021)

  • Hematoxylin and eosin staining of intact tissues via delipidation and ultrasound (Scientific Reports, 2018)

 

 

Sharada Mokkapati | Cancer Biology | Best Researcher Award

Published on by Global Academic Awards

Dr. Sharada Mokkapati | Cancer Biology | Best Researcher Award

Dr. Sharada Mokkapati, The UT MD Anderson Cancer Center, United States

Dr. Sharada Mokkapati is an Assistant Professor of Urology (Research) at UT MD Anderson Cancer Center, specializing in oncology, molecular biology, and gene therapy. With a PhD in Genetics from the University of Cologne, Germany (2007), Dr. Mokkapati has contributed significantly to bladder cancer research. She was a key team member in the first FDA-approved gene therapy for bladder cancer and has extensive experience with gene therapy vector development, RNA/DNA molecular techniques, and NextGen sequencing. Her research also includes the identification of miRNA biomarkers and the study of tumor metabolism in gene therapy responses. Dr. Mokkapati has received multiple awards, including the Dodie P. Hawn Fellowship and the Lennox K. Black International prize for excellence in medicine. She is also an adhoc reviewer for journals like BMC Cancer and has co-authored numerous influential publications on bladder cancer and cancer therapy.

Publication Profile

Scopus

Education

Dr. Sharada Mokkapati earned her PhD in Genetics from the University of Cologne, Germany, in February 2007. Her academic journey has focused on genetic research, exploring complex biological systems to understand various genetic disorders. With a robust foundation in genetic principles, she has contributed significantly to the scientific community through research, publications, and collaborations. Dr. Mokkapati’s work has emphasized advancing knowledge in molecular genetics, genetic markers, and hereditary diseases, making a lasting impact on the field. Her dedication continues to inspire the next generation of genetic researchers. 🌱📚

 

Professional Experience 🌟

Dr. Sharada Mokkapati has an extensive career in academia and research. Since 2020, she has served as an Assistant Professor in Urology (Research) at the UT MD Anderson Cancer Center. Previously, she was an Instructor in Urology (Research) at the same institution from 2015 to 2020. Dr. Mokkapati’s academic journey began with a postdoctoral fellowship in the Department of Genetics at UT MD Anderson Cancer Center (2008-2015). Her early career includes graduate studies in Dermatology at the University of Cologne (2002-2007), and research roles at SPIC Science Foundation and Malladi Drugs & Pharmaceuticals in India. 🧬🔬

 

 

Research Achievements 🧬🔬

Dr. Sharada Mokkapati has made significant contributions to the field of oncology and gene therapy. She was a key team member in the development of the first FDA-approved gene therapy for bladder cancer. With extensive experience in oncology, molecular biology, biochemistry, biotechnology, and biomedical research, Dr. Mokkapati has developed and validated vectors for gene therapy. She is highly proficient in RNA, DNA, protein molecular techniques, biochemical assays, and NextGen sequencing. Additionally, Dr. Mokkapati excels in using both xenograft and genetically engineered mouse models for translational biology studies and managing research-related compliance and clinical trial databases. 🧪💡

 

Awards and Honors 🏅🎓

Dr. Sharada Mokkapati has been recognized with several prestigious awards throughout her career. She was honored with the “Dodie P. Hawn Fellowship in Genetics” at UT MD Anderson Cancer Center. Dr. Mokkapati also received the “Travel Award-Lennox K. Black International Prize for Excellence in Medicine” for her contribution to the 12th International Symposium on Basement Membranes in Philadelphia. As a team member, she contributed to the technology transfer for amylase and tannase at SPIC Science Foundation, India. Additionally, she qualified the “National Eligibility Test for Lectureship (NET)” and received the “Dr. T. Ramachandra Rao Memorial Gold Medal” for academic excellence in her Master’s studies. 🏆🧬

 

 

Research Focus 🔬💡

Dr. Sharada Mokkapati’s research primarily focuses on oncology, molecular biology, and gene therapy in the context of bladder cancer. She has contributed extensively to the molecular profiling of bladder cancer, identifying relevant subtypes for biomarker discovery. Her work also includes the development and validation of gene therapy vectors, particularly in non-muscle invasive bladder cancer. Dr. Mokkapati is proficient in RNA/DNA/protein molecular techniques, biochemical analysis, and NextGen sequencing, using mouse models to address both basic biological and translational studies. Her efforts aim to integrate gene therapies into bladder cancer treatment paradigms. 🧬🧫🎯

 

Publication Top Notes

  • Molecular profiling of bladder cancer xenografts defines relevant molecular subtypes and provides a resource for biomarker discovery (2025) – Cited by 0 🔬📚
  • Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer (2025) – Cited by 0 🧬💡
  • Concomitant antihistamine administration improves survival outcomes in urothelial carcinoma treated with atezolizumab (2025) – Cited by 0 💊📈
  • Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model (2024) – Cited by 0 🧪🧬
  • Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval (2023) – Cited by 7 🏥🔬
  • The current status of gene therapy in bladder cancer (2023) – Cited by 8 📖🔍
  • Lentiviral interferon: A novel method for gene therapy in bladder cancer (2022) – Cited by 8 🧬🧪
  • Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer (2022) – Cited by 16 🧪🔬
  • TCF21 promotes luminal-like differentiation and suppresses metastasis in bladder cancer (2020) – Cited by 7 🧬💥
  • Generation of a novel mouse strain with conditional, cell-type specific, expression of DND1 (2019) – Cited by 2 🐁🔬

 

 

 

Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Published on by Global Academic Awards

Prof. Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Prof. Ammu Kutty Radhakrishnan, Monash University Malaysia, Malaysia

 

Prof. Ammu Kutty Radhakrishnan is a distinguished immunologist with a PhD from the University of Cambridge (1994), an MSc in Biochemistry (1990), and a BSc (First Class Honours) from the University of Malaya (1987). Currently, a Professor of Immunology at Monash University Malaysia, she has over 25 years of academic leadership and research experience. Prof. Ammu specializes in immunotherapy and food as medicine research, serving as Head of this research strength. Her career spans significant roles at International Medical University and Oxford. She is a research consultant, active in COVID-19 vaccine efforts, and supervises PhD and MSc students. 🌿🧬📚

 

Publication Profile

Google Scholar

Academic Excellence

Prof. Ammu Kutty Radhakrishnan has an exceptional academic background, with a PhD in Immunology from the University of Cambridge (1994) and degrees in Biochemistry from the University of Malaya. Her education forms a solid foundation for her expertise in immunology and biomedical sciences, contributing to her distinguished career.

Professional Experience

Prof. Radhakrishnan has held key roles, such as Professor at Monash University Malaysia and the International Medical University (IMU). Her leadership in academic programs, such as head of the Food as Medicine Research Strength and chief examiner roles, showcases her commitment to advancing education and research.

Research Contributions

Prof. Radhakrishnan has supervised numerous PhD and Master’s students, guiding 39 doctoral and 20 master’s research projects to completion. Her extensive research supervision experience highlights her dedication to fostering scientific inquiry and innovation. Additionally, her collaborative efforts with industry partners demonstrate her ability to apply research to real-world problems.

Conclusion

Prof. Ammu Kutty Radhakrishnan’s outstanding academic credentials, extensive research supervision, leadership roles, and global health contributions, she is an ideal candidate for the Best Researcher Award. Her work in immunology, biomedicine, and collaboration with industry partners demonstrates her excellence in both academic and applied research, making her a worthy contender for this prestigious recognition.

 

Publication Top Notes  

  • Protective effect of aqueous extract from Spirulina platensis against cell death induced by free radicals (2010) – 292 citations 🧪
  • Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59 (1994) – 259 citations 🧬
  • Rind of the rambutan, Nephelium lappaceum, a potential source of natural antioxidants (2008) – 193 citations 🍇
  • Current concepts of neurodegenerative mechanisms in Alzheimer’s disease (2018) – 176 citations 🧠
  • Bioactive Compounds: Natural Defense Against Cancer? (2019) – 169 citations 🌿
  • Protective mechanisms of flavonoids in Parkinson’s disease (2015) – 162 citations 🧑‍⚕️
  • Tocotrienol research: past into present (2012) – 157 citations 🌰
  • Standardised Mangifera indica extract is an ideal antioxidant (2009) – 149 citations 🥭
  • Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease (2020) – 128 citations 🚀
  • Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice (2004) – 126 citations 🧫
  • Rutin, a bioflavonoid antioxidant protects rat pheochromocytoma (PC-12) cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity (2013) – 124 citations 🧪

 

Roger KoggeEnang | Soil Science | Best Researcher Award

Published on by Global Academic Awards

Dr. Roger Kogge Enang | Soil Science | Best Researcher Award

Dr. Gabriel Espinosa Carrasco, University of Dschang, Cameroon

Dr. Roger Kogge Enang is a strong candidate for the Best Researcher Award due to his extensive background and contributions in soil science and environmental research. Here’s why he stands out:

Publication profile

Orcid

Extensive Research Output:

Since 2016, Dr. Enang has been actively publishing, with at least two scientific articles per year. His research spans various critical areas in soil science, including soil classification, nutrient cycling, and pollution remediation.

Educational Background:

He holds a Ph.D. and MSc in Soil Science, and a BSc in Chemistry, with a specialization in environmental chemistry and soil fertility. His academic credentials underpin his solid research foundation.

Diverse Research Interests:

His research covers vital topics such as soil mineralogy, soil organic matter, and digital soil mapping. He has contributed significantly to understanding soil properties and their implications for agriculture and environmental management.

Professional Involvement:

Dr. Enang is an active member of several professional organizations, including the Cameroon Soil Science Society and the International Network on Soil Pollution. His roles in these organizations reflect his commitment to advancing the field.

Field and Laboratory Experience:

His practical experience includes extensive soil surveys, experimental design, and advanced laboratory analyses. This hands-on expertise enhances the applicability and impact of his research findings.

Notable Publications:

Dr. Enang has published numerous peer-reviewed articles in reputable journals, demonstrating his ability to contribute valuable knowledge to the scientific community.

Given his track record of impactful research, extensive publications, and professional dedication, Dr. Roger Kogge Enang is highly suitable for the Best Researcher Award.

 

Gabriel Espinosa Carrasco | Cancer Immunology | Best Researcher Award

Published on by Global Academic Awards

Dr. Gabriel Espinosa Carrasco | Cancer Immunology | Best Researcher Award

Postdoctoral fellow Memorial Sloan Kettering Cancer Center Spain

Gabriel Espinosa Carrasco, Ph.D., is a seasoned immunologist renowned for his research on T cell dysfunction and immunotherapy. With a robust background in biological sciences and immunology, he has contributed significantly to understanding how different immune cell populations interact to combat cancer and autoimmune diseases. His career is marked by his leadership abilities and a strong network of collaborators in the immunology field.

 

Profile

Scopus

Education 🎓

Dr. Espinosa Carrasco holds a Ph.D. in Biological Sciences and Immunology from the University of Montpellier (2011-2016). He earned his Master’s in Advanced Immunology from the University of Barcelona in 2011 and a Bachelor’s degree in Biology from the Autonomous University of Barcelona in 2010.

Experience 🧑‍🔬

Currently, Dr. Espinosa Carrasco is a Post-doctoral Scholar at the Cancer Virotherapy and Immunotherapy Group at Bellvitge Institute for Biomedical Research (IDIBELL). He previously held a postdoctoral position at Memorial Sloan-Kettering Cancer Center, where he worked on projects related to intratumoral immune triads. His Ph.D. research at INSERM Unit 1183 focused on T cell interactions in autoimmune diabetes.

Research Interests 🔬

Dr. Espinosa Carrasco’s research interests lie in the development of new immunotherapies for solid tumors. He focuses on strategies to reverse T cell dysfunction, particularly the role of CD4 and CD8 T cells in tumor immunity. His work includes studying immune cell triads to enhance antitumor responses.

Awards 🏆

Dr. Espinosa Carrasco has received numerous accolades, including the 2024 Best Researcher Award (provisionally), a grant from the Ludwig Center for Basic and Translational Immunology, and the Third Prize Poster Presentation Award at the Tumor Microenvironments Symposium in 2019. He was also an invited seminar speaker at Georgetown University in 2017.

Publications Top Notes📚

Gabriel Espinosa-Carrasco et al. “Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.” Cancer Cell, 2024. 10.1016/j.ccell.2024.05.025 (Cited by 25 articles).

Mojdeh Shakiba, Gabriel Espinosa-Carrasco et al. “TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.” J Exp Med, 2022. 10.1084/jem.20201966 (Cited by 40 articles).

Sofia V. Gearty, Gabriel Espinosa-Carrasco et al. “An autoimmune stem-like CD8 T cell population drives type 1 diabetes.” Nature, 2022. 10.1038/s41586-021-04155-4 (Cited by 50 articles).

Gabriel Espinosa-Carrasco et al. “Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.01156 (Cited by 30 articles).

Gabriel Espinosa-Carrasco et al. “CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.02001 (Cited by 35 articles).